Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG-ABCAM Plc AGM Statement

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091102:RnsB7333B
                                                                                                                       .
RNS Number : 7333B  
  
ABCAM Plc  
  
02 November 2009  
  
 
  For immediate release   2 November2009  
  
  
ABCAM PLC  
  
("Abcam" or "the Company")  
  
AGM Statement   
  
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets 
antibodies via its own online catalogue, is holding its Annual General Meeting 
at 10.00 am this morning. As previously announced the Company's Chairman, David 
Cleevely, will be retiring from the Board at the AGM. Dr Cleevely will make the 
following statement at the meeting:   
  
"I am very proud of Abcam's achievements since we established the Company 11 
years ago. We have built a global business characterised by rapidly increasing 
demand for its products and a strong customer base. In recent times the strength 
of our business model has come to the fore and the robust and defensive nature 
of the markets we serve has been demonstrated."  
  
"I am pleased to report that the Company has continued to perform well in the 
new financial year. Underlying sales growth is in line with our expectations as 
demand for our products increases and we are benefiting from the weakness of 
sterling over the comparative period last year. The challenges to the global 
economy as a result of the recession require a degree of caution, but the Board 
looks forward to another successful year."  
  
For further information please contact:   
  
Abcam         + 44 (0) 1223 696000   
  
Jonathan Milner, Chief Executive Officer   
  
Jeff Iliffe, Chief Financial Officer   
  
www.abcam.com   
  
Numis Securities         + 44 (0) 20 7260 1000   
  
Michael Meade / Nick Westlake - Nominated Adviser  
  
James Black - Corporate Broking  
  
Buchanan Communications    + 44 (0) 20 7466 5000   
  
Mark Court / Stasa Filiplic  
  
Notes for editors  
  
About Abcam plc  
  
Abcam is a producer and distributor of research-grade antibodies headquartered 
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, 
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and 
trades under the ticker symbol ABC. The Company produces and distributes its own 
and third-party produced antibodies to academic and commercial users throughout 
the world. Product ordering is available through the Company's website 
www.abcam.com, where customers are also able to access up-to-date and detailed 
technical product data sheets. All the antibodies are sold under the Abcam brand 
name and the Company's vision is to build the world's largest online resource of 
high-quality and commercially viable antibodies. Abcam now has an online 
catalogue of over 56,000 products, most of which are antibodies, from over 250 
suppliers and employs 243 staff in its four operating companies.   
  
About antibodies  
  
Antibodies are proteins produced by white blood cells in response to the 
introduction of a foreign body known as an antigen. Antibodies, which have a 
wide variety of uses in research, diagnostics and therapeutics, are used by 
bioscientists in research into disease and into the human genome, where they are 
used to mark and identify specific cells and other living matter. The number of 
human antibodies of use in research is potentially greater than one million.   
  
 
This information is provided by RNS  
  
The company news service from the London Stock Exchange  
  
  END  
  
AGMCKDKBABDDCDK  
  

---

back to RNS news